Recombinant Human A1AT Protein，His

Alpha-1 antitrypsin (A1AT) is a key protein synthesized in the liver that plays a crucial role in protecting tissues from enzymes of inflammatory cells, particularly neutrophil elastase. Deficiency in A1AT can lead to severe lung diseases, such as emphysema and chronic obstructive pulmonary disease (COPD), and liver disorders, including cirrhosis. The inheritance of A1AT deficiency occurs due to mutations in the SERPINA1 gene, leading to a range of phenotypes, the most common being the PiZZ genotype associated with significant clinical manifestations. Recent advancements in biotechnology have paved the way for the development of recombinant A1AT proteins to treat A1AT deficiency. These recombinant proteins are engineered to enhance stability, bioavailability, and functional activity in the body. Research has focused on optimizing the expression systems for producing A1AT, such as using mammalian cells or yeast, which can yield properly glycosylated and functional proteins. Clinical studies have indicated that recombinant A1AT therapy can improve lung function and reduce the incidence of liver damage in affected individuals. Ongoing research aims to refine the production processes, assess long-term efficacy, and explore the potential of A1AT as a therapeutic agent beyond deficiency-related diseases, including its anti-inflammatory and tissue-protective properties in various conditions such as cystic fibrosis and chronic inflammatory diseases. The growing understanding of A1AT's mechanisms of action and potential therapeutic applications underscores the importance of continued research in this area for developing novel treatment strategies to improve patient outcomes.